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In this review article, we present recent updates on the hematologictumor microenvironment following the 3rd Scientific Workshop on theHaematological Tumour Microenvironment and its Therapeutic
Targeting organized by the European School of Hematology, which took
place at the Francis Crick Institute in London in February 2019. This review
article is focused on recent scientific advances highlighted in the invited pre-
sentations at the meeting, which encompassed the normal and malignant
niches supporting hematopoietic stem cells and their progeny. Given the
precise focus, it does not discuss other relevant contributions in this field,
which have been the scope of other recent reviews. The content covers
basic research and possible clinical applications with the major therapeutic
angle of utilizing basic knowledge to devise new strategies to target the
tumor microenvironment in hematologic cancers. The review is structured
in the following sections: (i) regulation of normal hematopoietic stem cell
niches during development, adulthood and aging; (ii) metabolic adaptation
and reprogramming in the tumor microenvironment; (iii) the key role of
inflammation in reshaping the normal microenvironment and driving
hematopoietic stem cell proliferation; (iv) current understanding of the
tumor microenvironment in different malignancies, such as chronic lym-
phocytic leukemia, multiple myeloma, acute myeloid leukemia and
myelodysplastic syndromes; and (v) the effects of therapies on the microen-
vironment and some opportunities to target the niche directly in order to
improve current treatments.
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ABSTRACT
The normal niches in development, adulthood and aging
A maladapted vascular niche induces the generation and expansion 
of tumor-initiating cells
Work from Dr. Rafii’s laboratory, among others, has revealed the heterogeneity of
endothelial cells, which comprise over 140 different types of endothelium in the
human body. Each organ or tumor is vascularized by a specialized endothelium. It is
believed that transcription factors belonging to the Ets family, such as Ets variant 2
(ETV2), Fli1 and the Ets-related gene (Erg), make endothelial cells organ-specific.
Endothelial cells are important niche cells for hematopoietic stem cells (HSC) and
their use as feeder cells in culture allows the expansion of HSC by ~150-fold.1 As a
refinement, a combination of reprogramming factors, including FBJ murine osteosar-
coma viral oncogene homolog B (FOSB), growth factor independent 1 transcriptional
repressor (GFI1), runt-related transcription factor 1 (RUNX1) and SPI1 (which
encodes PU.1), can be combined with sustained vascular niche induction to generate
HSC that are endowed with secondary repopulating activity.
However, a maladapted vascular niche can facilitate the expansion of tumor-initi-
ating cells in different organs. A paradigm-shifting concept
over the past few years is that blood vessels not only deliver
nutrients and oxygen to organs and tissues, but that they
also sustain stem cells and cancer cells through an
'angiocrine’ mechanism. Consequently, maladapted tumor-
associated vascular endothelial cells may confer stem cell-
like activity to indolent tumor cells. One example of this is
the conversion of dormant lymphoma cells into aggressive
lymphoma through the interaction with endothelial cells.
This effect is dependent on Notch signaling, since Jagged1
abrogation in endothelial cells can slow down lymphoma
progression.2 Another example is the abnormal activation
of the fibro blast growth factor receptor 1 (FGFR1)-ETS2
pathway in tumor-associated-vascular endothelial cells dur-
ing chemotherapy. Specifically, tumor-derived FGF4 acti-
vates FGFR1 in endothelial cells and induces the expression
of the transcription factor ETS2. Chemotherapy inhibits the
tumor-suppressive checkpoint function of insulin growth
factor binding protein 7 (IGFBP7)/angiomodulin and
increases the expression of insulin growth factor 1 (IGF1) in
endothelial cells, causing an FGFR1-ETS2 feedforward loop
which renders naïve IGFR1+ cancer cells resistant to
chemotherapy.3 This research helped to show that the
FGF4-FGFR1-ETS2 pathway plays  a crucial role in tumor-
associated endothelium.
Angiocrine signals regulate quiescence and therapy
resistance in bone
Kusumbe and colleagues characterized different vessel
subtypes comprising endothelial and sub-
endothelial/perivascular cells in murine bone marrow. Type
H endothelium (named so because of its high expression of
endomucin) nurtures bone-forming cells during develop-
ment.4 However, alterations of the vascular microenviron-
ment can affect the fate of disseminated tumor cells.5
Dormant tumor cells can be awakened through the produc-
tion of factors such as periostin (POSTN) and transforming
growth factor β-1 (TGFβ-1). Importantly, proximity to the
sprouting vasculature supports cancer cell proliferation,
whereas a stable vasculature keeps cancer cells dormant. In
relation to this, vascular remodeling during aging might
alter hematopoiesis. For instance, type H endothelium and
its associated osteoprogenitor cells are reduced during
aging, possibly affecting hematopoiesis. Consistent with
these results, reactivation of endothelial Notch signaling
can activate HSC in aged mice, although it cannot fully
restore HSC self-renewal.6 Age-associated vascular remod-
eling might facilitate the development of myeloid malig-
nancies since it promotes myeloid cell expansion.7
The hematopoietic stem cell niche in aging
In this regard, Geiger et al. uncovered several microenvi-
ronmental contributions to HSC aging. It had been previ-
ously reported that aged stromal cells secrete more pro-
inflammatory CC-chemokine ligand 5 (CCL5 or RANTES)
but less osteopontin (OPN); these stromal changes imprint
some aging-associated phenotypes in HSC.8 Specifically, a
decreased frequency of endosteal stromal cells and
osteoblasts reduces OPN expression, which is associated
with HSC aging (manifested as myeloid skewing). The
bone marrow microenvironment of adult OPN knockout
mice partly resembles an aged wildtype microenvironment
in its increased number of HSC which exhibit reduced
engraftment and polarity. However, treatment with OPN
fraction D can attenuate the dysfunction of aged long-term
HSC (LT-HSC) and ameliorates HSC by activating integrin
α9β1 in HSC.9 Additionally, aged endothelial cells drive
hematopoietic aging phenotypes in young HSC, whereas
infusion of young endothelial cells enhances endogenous
HSC activity in aged mice.10
Metabolism in the tumor microenvironment
Intense efforts are currently being expended to elucidate
how cancer cells reshape their malignant microenviron-
ment to increase their metabolic fitness and chemoresis-
tance.
Subversion of systemic glucose metabolism 
as a mechanism to support the growth of leukemic cells
Work by Dr. Ye and colleagues in Dr. Jordan’s laboratory
has revealed how leukemic cells subvert the metabolism of
systemic glucose for their proliferation. Insulin resistance,
besides playing a key role in obesity and diabetes, may
facilitate leukemogenesis: leukemic cells can actively reduce
glucose utilization by normal tissues to increase their glu-
cose bioavailability.11 Collectively, the findings suggest that
leukemic cells increase IGFBP1 production from adipose tis-
sue, which can cause insulin resistance. An intricate com-
munication with the gut causes loss of active glucagon-like
peptide-1 (GLP1) and serotonin, which suppresses insulin
secretion. Overall, these systemic perturbations are
believed to cause desensitization of normal tissues to glu-
cose, suggesting a novel therapeutic window based on the
restoration of normal glucose regulation.
Mitochondrial trafficking in the tumor microenvironment
Mitochondria are emerging components in the molecular
exchange between leukemic cells and their microenviron-
ment. The ability of bone marrow mesenchymal stromal
cells (BMSC) to donate mitochondria to different cell types12
has emerged as a potentially important process in hemato-
logic diseases. Mitochondrial transfer has recently been
appreciated to be a previously unrecognized mechanism of
intercellular communication associated with chemoresis-
tance.13,14 Tunneling nanotubules appear to be the primary
mitochondrial exchange route used in acute myeloid
leukemia (AML).14 Work from Dr. Rushworth’s laboratory
indicates that NADPH oxidase 2 (NOX2)-derived reactive
oxygen species, induced by H2O2 or daunorubicin, may
enhance mitochondrial transfer from BMSC to AML blasts.
The transferred mitochondria appear functionally active and
capable of boosting metabolic activity in AML cells.13 A sim-
ilar process has been reported in multiple myeloma.
Increased oxidative phosphorylation (OXPHOS) in multiple
myeloma cells is associated with CD38-driven mitochondr-
ial transfer.15 It is worth noting that this process seems to
affect malignant cells preferentially and is not frequently
observed in their normal counterparts. Therefore, a potential
therapeutic window might be available through blockade of
mitochondrial transfer.
Fatty acid metabolism and bone marrow adipocytes in
acute myeloid leukemia
Work from Dr. Tabe’s and Dr. Andreeff’s laboratories has
revealed other metabolic changes in AML, particularly
focused on the role of adipocytes and fatty acid metabo-
lism. Fat cells are a predominant type of stromal cell in aged
human bone marrow. BMSC can promote AML survival
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through a metabolic shift from OXPHOS to fatty acid oxi-
dation, which causes OXPHOS uncoupling.16 In addition,
leukemia stem cells express the fatty acid receptor CD36
and exhibit high levels of fatty acid oxidation, associated
with cell quiescence and drug resistance.17 However, a novel
small molecule inhibitor of fatty acid oxidation, avocatin-B,
selectively inhibits AML and leukemia stem cells without
detectable toxicity in normal HSC. Avocatin-B increases
fatty acid uptake and enhances the expression of fatty acid-
binding protein-4 (FABP4) in adipocytes co-cultured with
AML cells. However, concomitantly, avocatin-B increases
glucose uptake and glycolysis in AML, thus contributing to
AML survival.18 Overall, these data highlight the limitations
of targeting a single metabolic pathway, since leukemic cells
may escape through metabolic adaptation. Accordingly,
cytarabine-resistant AML cells exhibit increased fatty acid
oxidation and OXPHOS. Fatty acid oxidation inhibition
induces an energy shift from high to low OXPHOS that
enhances anti-leukemia effects, but only in combination
with cytarabine.19 Inhibition of fatty acid oxidation addi-
tionally activates the endoplasmic reticulum stress activator
transcription factor 4 (ATF4) and enhances cytarabine
cytoxicity in AML cells co-cultured with bone marrow
adipocytes.20 These findings suggest that combined thera-
pies containing inhibitors of fatty acid oxidation could be
capable of targeting metabolic vulnerabilities in AML.
Inflammation and cell cycle
One hallmark of hematologic malignancies is a proin-
flammatory state whereby inflammatory cytokines affect
the proliferation of normal and mutant cells. Inflammation
is, therefore, one key trigger of the reshaped malignant
microenvironment.
Impact of aged marrow macrophages on hematopoietic
stem cells and their niche
Microenvironmental inflammation is another driver of
hematopoietic aging. Previous studies have shown that
aged CD41+ LT-HSC accumulate during aging and their
megakaryocyte bias results in increased circulating platelets
in aged mice.21-24 Calvi et al. have shown that aged bone
marrow macrophages contribute to the expansion of
platelet-based HSC through interleukin-1β.25 Aged murine
bone marrow macrophages exhibit an activated phenotype
and defective phagocytic function, which causes reduced
efferocytosis of senescent neutrophils. In vitro co-culture
systems suggest that increased interleukin-1β and reduced
Axl receptor tyrosine kinase and its associated protein
growth arrest-specific 6 (Gas6) contribute to platelet skew-
ing during aging.
Hematopoietic stem cells and their bone marrow niche
under inflammatory stress
Inflammation can affect both HSC and their niches.
Infection can cause stress and dysfunction in HSC respond-
ing to infection. Chemotherapy, transplantation or inflam-
matory cytokines, such as interferon (IFN)-α, can modify
HSC quiescence and make HSC re-enter the cell cycle.26-29
For example, acute or non-acute virus infections activate
quiescent LT-HSC but also affect their function through IFN-
I receptor signaling.29 Non-acute murine cytomegalovirus
infections alter the LT-HSC gene expression profile and
impair HSC function upon transplantation. One mediator
appears to be the extracellular matrix adaptor protein
Matrilin-4 (Matn4), which is a candidate negative regulator
of HSC proliferation under stress.29 Under acute stress,
Matn4 expression decreases, allowing for HSC expansion to
replenish the blood system. Importantly, reduced expression
of the Cxcl12/Sdf-1 receptor Cxcr4 in Matn4-/- HSC
improves the reconstitution and expansion of HSC. On the
non-hematopoietic side, endothelial cells proliferate after
inflammatory stress or infection to maintain vessel integrity
and permeability. The responses of endothelial cells to IFN-
α in vivo are transient and dependent on the expression of
IFN-α receptors. In this regard, vascular endothelial growth
factor (VEGF) has emerged as one mediator of the activation
of bone marrow endothelial cells by IFN-α-stimulated
hematopoietic cells. In conclusion, as part of the dynamic
crosstalk between HSC and their niches, inflammatory
stress not only has an impact on HSC but also on their
microenvironment and this altered bidirectional crosstalk
affects the growth and function in each compartment.
The bone marrow microenvironment in myeloproliferative
neoplasms
Associated with inflammation, bone marrow fibrosis is
an extensive remodeling of the bone marrow extracellular
matrix, which is typically observed in some myeloprolifer-
ative neoplasms. Previous studies found that damage to the
bone marrow microenvironment contributes to the pro-
gression of myeloproliferative neoplasms.30 However, the
identification of fibrosis-driving cells and specific markers
of a pre-fibrotic state are important therapeutic issues that
remain only partially addressed. Schneider and colleagues
described GLI family zinc finger 1 (Gli1)+ mesenchymal
stromal cells as fibrotic cells in different types of fibrosis.
Gli1+ cells appear to be myofibroblast precursors which
contribute significantly to myelofibrosis. Accordingly,
genetic ablation of Gli1+ cells reduces fibrosis and improves
hematopoiesis in experimental models.31
Regulation of dormant hematopoietic stem cells
Inflammation is only one of the mechanisms that can
awaken dormant HSC, as shown in studies by Cabezas-
Wallscheid and colleagues. Dormant HSC can now be iden-
tified with specific markers, such as Lineage−Sca-1+c-Kit+
(LSK) CD150+CD48−CD135−CD34− cells expressing the G
protein-coupled receptor Gprc5c5.32 Dormant HSC repre-
sent only a very small subset of bone marrow cells, but
these cells harbor the highest long-term reconstituting
potential. Dormant HSC are characterized by low levels of
biosynthetic processes (transcription, mRNA processing
and translation) which gradually increase as the HSC
become activated. Retinoic acid/vitamin A-induced signal-
ing is highly enriched in dormant HSC and contributes to
maintain low levels of reactive oxygen species, protein
translation and expression of the proto-oncogene c-myc in
these cells. In vivo, pre-treatment with all-trans retinoic acid
can preserve HSC quiescence upon stress induced by
chemotherapy or lipopolysaccharide. These results suggest
that retinoic acid might restrict HSC proliferation. In con-
trast, lack of vitamin A compromises HSC re-entry into dor-
mancy after exposure to inflammatory stress.32
Molecular regulation and heterogeneity in the exit from
quiescence by human hematopoietic stem cells
Not only the actual quiescence of HSC, but also the time
that that these cells take to enter the cell cycle can be a
D. Forte et al.
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defining feature, as revealed by Laurenti and colleagues. In
fact, LT-HSC take longer than short-term HSC to enter the
cell cycle. Cyclin dependent kinase-6 (CDK6) expression
controls the exit from quiescence in human HSC.33
Consequently, enforced CDK6 expression can push LT-
HSC to divide as quickly as short-term HSC. Human HSC
heterogeneity and lineage commitment were dissected fur-
ther in a subsequent study. The first lineage restriction
appears to affect the CD19–CD34+CD38–CD45RA–
CD49f+CD90+ HSC compartment’s generation of myelo-
lymphoid committed cells which are devoid of erythroid
differentiation capacity. The expression of the C-type lectin
domain family 9 member A (CLEC9A) and CD34 in these
cells can be used to distinguish CLEC9AhiCD34lo LT-HSC
(with slow exit from quiescence) from CLEC9Alo CD34hi
myelo-lymphoid-restricted HSC (with quicker entry into
the cell cycle).34 These results help identify human HSC
subsets and will be very useful to study their interactions
with bone marrow microenvironments.
Interaction of tumor cells with their 
microenvironment
Mapping the bone marrow microenvironment in sickness
and in health
The development of single-cell technologies has made it
possible to generate an atlas of different tissues at single-cell
resolution. A recent study by Dr. Aifantis’ group presented
the transcriptional signatures of murine bone marrow vas-
cular endothelial cells, perivascular cells and
osteolineage/stromal cell populations under steady state or
under stress (5-fluorocuracil), with a major emphasis on
candidate cellular sources of key factors regulating
hematopoiesis.35 For example, the loss of the delta-like
canonical Notch ligand 4 (DLL4) in endothelial cells caused
profound transcriptional changes, which drove myeloid
skewing of HSC/progenitors.
Targeting the microenvironment in smoldering myeloma
Like other hematologic malignancies, multiple myeloma
involves a multistep transformation process36 with con-
comitant remodeling of the BM microenvironment,37 as
shown by Ghobrial et al. However, studies on the human
bone marrow microenvironment are frequently challenged
by the scarcity and insufficient preservation of tissue biop-
sies for detailed studies. A potential way to replace bone
marrow biopsies might be to combine whole-exome
sequencing of circulating tumor cells and cell-free DNA,
which might help our understanding of disease heterogene-
ity and evolution in multiple myeloma.38 Cell-free DNA
reveals a similar clonal structure as bone marrow biopsies,39
potentially paving the path for less invasive mutational
screening.
Investigating mechanisms regulating myeloma growth
and dissemination using in vivo bone marrow imaging
Studies by Dr. Fooksman and others have showed the
potential of intravital microscopy for studying the interac-
tions of normal and mutant hematopoietic cells with their
microenvironment. Antibody-secreting cells comprise
mature plasma cells and more immature plasmablasts
which can be identified by the expression of syndecan-1
(CD138), a marker with an unclear function until recently.
CD138 has lately been found to promote the survival of
antibody-secreting cells through IL-6 and A proliferation-
inducing ligand (APRIL).40 Therefore, ongoing studies are
utilizing similar intravital imaging techniques to study the
microenvironment in multiple myeloma and other hemato-
logic malignancies.
The tumor microenvironment in chronic 
lymphocytic leukemia, plasma cell myeloma 
and myelodysplastic syndromes
Understanding and targeting tumor-microenvironment
interactions in B-cell malignancies
Microenvironmental alterations can be putative thera-
peutic targets in B-cell malignancies, as revealed by
Ringshausen et al. The expression of protein kinase C beta
II (PKCβ2) and downstream activation of NF-kappa B
(NFkB) in BMSC is required for the survival of malignant B
cells.41 Chronic lymphocytic leukemia (CLL) cells induce
Notch2 signaling and complement C1q production by
BMSC, which in turn inhibits glycogen synthase kinase 3
beta (GSK3β)-dependent degradation of β-catenin in CLL.
Additionally, Notch2 activation in BMSC further stabilizes
β-catenin in CLL through regulation of N-cadherin expres-
sion. Consequently, inhibition of Notch or Wnt pathways
has therapeutic effects in experimental CLL models.42
The biological and clinical roles of the microenvironment
in chronic lymphocytic leukemia
Work in Dr. Hallek’s laboratory and others has illustrated
how CLL becomes addicted to the microenvironment, and
particularly to macrophages or nurse-like cells. A prominent
example is the non-receptor tyrosine-protein kinase Lyn
belonging to the SRC family, which is crucial both for B-cell
receptor signaling and for microenvironmental support of
the malignant cells.43 Lyn-deficient mice present a reduced
CLL burden. However, the loss of Lyn in B cells only
reduces B-cell receptor signaling, but does not affect CLL
progression. In fact, Lyn is required in microenvironmental
cells (and particularly macrophages) for the expansion of
CLL cells.
Pre-clinical modeling of myelodysplastic syndromes 
in murine xenograft models
The clinical heterogeneity and molecular complexity of
myelodysplastic syndromes (MDS) make these diseases
arduous to model and study. However, xenograft models
have emerged as useful tools for studying MDS. Co-trans-
plantation of CD34+ cells with patient-derived BMSC has
been reported in one study to increase long-term engraft-
ment of human MDS in immunodeficient mice.44 In that
study, patient-derived hematopoietic cells prompted
healthy BMSC to acquire MDS-BMSC-like features.
Consequently, cytokines produced by MDS BMSC favored
the propagation of MDS after orthotopic interfemoral
transplantation into immunodeficient mice. However, this
finding contrasts with that of another study which found
similar engraftment of MDS regardless of the presence of
human BMSC.45 It is possible that technical differences
and/or distinct diseases/stages underlie these divergent
results. Moreover, due to recent advances in bioengineering
and carrier materials, traditional xenotransplants are being
progressively replaced by bioengineered humanized
microenvironments. As one example, implantable scaffold
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methods allow the study of multicellular interactions
between human stromal cells and HSC.46
Targeting the tumor microenvironment
Targeting the tumor microenvironment in B-cell
lymphomas
Other ways to target the tumor microenvironment in B-
cell malignancies have been exemplified by research in Dr.
Gribben’s laboratory and take advantage of the fact that
lymphoma cells live in an immune cell-enriched microenvi-
ronment. However, immune cells do not function normally
because CLL or lymphoma cells reduce the F-actin immune
synapse formation in tumor-infiltrating T cells.
Nonetheless, impaired T-cell function can be therapeutical-
ly reverted by the immunomodulatory drug lenalidomide.47
which has recently been approved for the treatment of lym-
phoma. In a subsequent study, the inhibitory B7-related
molecules CD200, CD274 (PD-L1), CD276 (B7-H3) and
VD270 (HVEM) were identified as key mediators of the T-
cell synapse defect.48 Consequently, the PD1-PDL1 axis has
emerged as a highly promising target in CLL and lym-
phoma.49,50 These results have been extrapolated to solid
tumors, in which PD1 expression has become both a bio-
marker and a therapeutic target.
Engineering T cells to overcome the immunosuppressive
tumor microenvironment
Engineered T cells can be used to overcome the immuno-
suppressive tumor microenvironment. Generating tumor-
specific lymphocytes has proven challenging given that
many tumors are not very immunogenic. A revolutionary
approach in immunotherapy is to combine the variable
regions of antibodies (which recognize epitopes shared by
tumors) with the constant regions of the T-cell receptor to
generate chimeric antigen receptor (CAR) T cells.51 This
approach has been improved recently by adding co-stimu-
latory domains. CD19-specific CAR-T cells have provided
impressive results in acute lymphoblastic leukemia, with
reported cure of chemorefractory disease. Some lessons
learned from these studies are: (i) chemotherapy is essen-
tial; (ii) it is critical to include a co-stimulatory domain; (iii)
targeting a single antigen may enable immune escape; and
(iv) significant toxicities (neural, cytokine storm) should be
avoided in the future by improving the specificity and effi-
cacy of the approach (to reduce the number of CAR-T cells
infused). However, despite the impressive positive results
of CD19-specific CAR-T cells in acute lymphoblastic
leukemia, AML has proven more difficult to treat. In this
regard, integrated transcriptomics and proteomics have not
identified single candidate targets in AML, although combi-
natorial strategies have been proposed.52,53
Targeting altered metabolism in the leukemia 
microenvironment
It is now clear that the bone marrow microenvironment
rewires energy metabolism in AML; however, targeting
metabolic vulnerabilities in AML has proven challenging
given the high degree of metabolic adaptation in AML cells.
One key driver of metabolic reprograming in the leukemic
bone marrow microenvironment is hypoxia. Most tumors
are typically hypoxic, as cancer cells avidly consume oxy-
gen and blood vessels become progressively compressed or
obstructed by the growing tumor mass. Cancerous tissue in
both solid and liquid tumors develops chronic hypoxia,
which is associated with resistance to therapy and immune
suppression.54 However, the role of (low) oxygen in the pro-
gression and chemoresistance of leukemia remains contro-
versial. Recently, a hypoxia-activated prodrug (TH-302)
was tested in models of AML in vivo.55 TH-302 is able to
eliminate cancer cells residing in hypoxic microenviron-
ments. Hypoxic niches were increased in a syngeneic AML
murine model, but AML cells surviving chemotherapy
could be targeted by TH-302, which improved mouse sur-
vival. On the other hand, metabolic reprogramming was
previously reported to become more dependent on glyco -
lysis. However, recent findings have challenged this view
by showing that many tumors rely primarily on OXPHOS.
Although targeting OXPHOS clinically presents some
obstacles, drugs such as IACS-010759, a highly effective
and selective small-molecule inhibitor of complex I of the
mitochondrial electron transport chain, can reduce tumor
burden in experimental models of brain cancer and AML.56
Interferon in myeloproliferative neoplasms
Connected with the effects of IFN-α on HSC and their
microenvironment described above, studies by Dr.
Kiladjian and others have shown that IFN-α is one of very
few drugs capable of reducing the mutant allele burden in
myeloproliferative neoplasms. Ropeginterferon triggered a
dose-dependent anti-proliferative effect in JAK2V617F-
mutated cell lines, whereas it did not affect the differentia-
tion of normal CD34+ cells.57 One possibility might be to
combine IFN with JAK inhibition, since the latter does not
seem to modify the allele burden, but does dampen inflam-
mation. IFN has been shown to induce molecular
histopathological responses in myelofibrosis but it also
induces immune and inflammatory toxicity. Ruxolitinib
may offset IFN toxicity and the combination of these two
drugs might enhance the molecular and histopathological
response rate. However, it is possible that the anti-JAK1
activity of ruxolitinib might antagonize IFN signaling.
These issues remain to be investigated in future studies.
CXCR4 inhibitors
The CXCL12-CXCR4 axis regulates bone marrow hom-
ing, retention, proliferation and egress of HSC and also
affects the traffic of leukocytes. In particular, CXCR4 expres-
sion in HSC is necessary to keep these cells in the CXCL12-
enriched bone marrow microenvironment. Dr. Peled and
others have shown that efficient blockade of CXCR4 mobi-
lizes HSC from the bone marrow into the circulation.
Plerixafor (AMD3100) is a first-generation CXCR4 antago-
nist which has low affinity for the receptor. It is approved
for HSC mobilization (but only in combination with granu-
locyte colony-stimulating factor) for the treatment of multi-
ple myeloma and non-Hodgkin lymphoma. The new-gener-
ation CXCR4 inhibitor BL8040 binds CXCR4 with higher
affinity (1-2 nM) than AMD3100 (84 nM).58 In addition,
whereas AMD3100 rapidly dissociates from CXCR4,
BL8040 behaves as an inverse agonist and has a slow off-
rate, causing more sustained CXCR4 inhibition. CXCR4
directly or indirectly stimulates tumor growth and regulates
stromal cell adhesion-mediated drug resistance to
chemotherapy. BL8040 can induce the mobilization of AML
cells into the circulation and promote AML differentiation
and apoptosis. A synergistic effect can be observed in com-
bination with FLT3 or BCL-2 inhibitors,59 suggesting that
combination therapies could be useful in AML. 
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New insights into early-stage bone colonization 
of disseminated cancer cells
Finally, solid cancers can metastasize into bone after
hijacking the normal bone marrow microenvironment, as
illustrated by the work of Dr Zhang and others. Upon col-
onization of the bone marrow, cancer cells dysregulate
bone formation and degradation cycles and stimulate the
release of factors that promote tumor growth in a vicious
cycle. Ell & Kang stated that: “TGFβ, insulin-like growth
factor (IGF), and calcium are released from the bone matrix
during lysis, enhancing tumor proliferation and survival.
TGFβ signaling in tumor cells enhances expression of bone
metastasis proteins including parathormone-related protein
(PTHrP), the Notch ligand Jagged1, connective tissue
growth factor (CTGF), IL-11, and matrix metalloproteinas-
es. Calcium signaling through the calcium-sensing receptor
leads to increased proliferation and survival. Osteoblasts
also secrete a number of proteins that positively regulate
tumor growth, including IL-6, secreted protein acidic and
cysteine rich (SPARC) and periostin. SPARC induces cancer
migration and homing through the αVβ5 integrin, whereas
periostin and IL-6 promote tumor survival”.60
Whereas many molecules driving metastatic growth have
been identified, there is an important lack of knowledge
regarding mechanisms allowing cancer cell colonization
and maintenance before expansion. The microenvironment
of early-stage bone lesions appears to be primarily an
osteogenic niche composed of alkaline phosphatase (ALP)+
collagen-I (ColI)+ cells which define a preosteolytic stage
(osteoclasts are not yet predominant at this early stage).
Cancer and osteogenic niche cells generate heterotypic
adherent junctions formed by E-cadherin and N-cadherin.
E-cadherin blockade can abolish spontaneous bone metas-
tases in a manner dependent on mammalian target of
rapamycin (mTOR) and p70.61 Moreover, cancer cells and
niche cells are connected by gap junctions formed by con-
nexin (Cx)43, which is induced in cancer cells after bone
marrow colonization. Cx43 allows for calcium transfer to
cancer cells to drive mTOR-dependent metastatic growth.
This pathway can be inhibited by danusertib or a combina-
tion of everolimus and arsenic trioxide.62 This research illus-
trates how solid tumors may hijack normal bone marrow
niches to drive metastatic growth.
Summary
Increasingly, the tumor microenvironment is the focus of
studies addressing survival, growth and chemoresistance of
solid tumors and hematologic malignancies since it plays
critical roles in disease initiation, maintenance and relapse.
A key challenge is the dual role of the microenvironment in
regulating normal and malignant hematopoiesis, since
inhibiting the development and maintenance of malignan-
cies must be followed by the reestablishment of normal tis-
sue function. Therapies targeting the tumor microenviron-
ment (which not only comprises the immune system, but
also the stromal and endothelial cells that interact with the
malignant cells and the immune cells) must simultaneously
eliminate chemoresistant cells and preserve/reestablish nor-
mal hematopoiesis. Multidisciplinary meetings uniting
basic and clinical researchers concerned about the tumor
microenvironment have proven a unique opportunity for
cross-fertilization of scientific knowledge, ideas and
approaches to identify key vulnerabilities of the malignant
niches.
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